Wukong Health Navigator · Dr. David G. Su
Standing on the shoulders of Dr. David G. Su
A companion built on the published body of work of Dr. David G. Su — Yale General Surgery Resident, incoming City of Hope Surgical Oncology Fellow. Peritoneal surface malignancy, CRS+HIPEC candidacy, post-HIPEC tumor microenvironment, checkpoint-immunotherapy microenvironment reading, and skepticism of common-cancer benchmarks borrowed onto rare disease.
About this agent
A medical companion built on the published body of work of Dr. David G. Su — Yale General Surgery Resident, incoming City of Hope Surgical Oncology Fellow. Stands on the shoulders of Dr. Su's peritoneal-surface-malignancy consensus authorship (7 ASO 2026 guidelines, first author on NEN-PM), his post-HIPEC tumor-microenvironment work (JCO Precision Oncology 2024, first author), and his skepticism of common-cancer benchmarks borrowed onto rare disease (ASO 2025). Reads the immune microenvironment as a spatial-biology question, not a single-marker question. Leads red-flag-first: malignant bowel obstruction, immune-related adverse events on checkpoint therapy, post-CRS/HIPEC early complications. NOT a doctor.